Startups channel feed

With $270M in new funds, Shankar Ra­maswamy looks be­yond Roivant in scal­ing his gene ther­a­py 'con­sol­i­dat­ed en­gine'

Shankar Ramaswamy doesn’t intend to repeat the Roivant playbook that his brother started eight years ago. Instead, he wants to consolidate the gene therapy process and be the go-to shop in a field that has ridden a rocky road for many years.

Amid a bear market, he and his 160-employee biotech have reeled in a $270 million Series C.

“Notwithstanding the broader market conditions, I think we are building a very different type of company that I think resembles what we’ve seen in other modalities, whether it’s in mRNA, or monoclonal antibodies, or RNAi technologies,” Ramaswamy told Endpoints News.

Pamela Conley, Nuvig Therapeutics co-founder and CEO

With 30-year in­dus­try chops, Pamela Con­ley launch­es a pro­tein ther­a­peu­tics biotech for au­toim­mune dis­eases

After about 17 years at Portola Pharmaceuticals, Pamela Conley was ready for her next venture once helping transition some of the drugmaker’s programs into Alexion in mid-to-late 2020.

Since then, she’s been setting up shop at autoimmune-focused Nuvig Therapeutics, which broke cover Wednesday with $47 million from Novo Holdings, Platanus, Bristol Myers Squibb, Digitalis Ventures and Mission BioCapital.

Asit Parikh, MOMA Therapeutics CEO

Work­ing like a ma­chine dur­ing the pan­dem­ic, MO­MA taps in­vestors to bankroll its 'mol­e­c­u­lar ma­chi­nes'

For a biotech that opened its lab the week before the pandemic shuttered many offices, MOMA Therapeutics has experienced hardly a blip in operations, so much so that it attracted 15-year Takeda vet Asit Parikh last year as CEO and — amid a wilting financing environment — a $150 million Series B to take on the machine.

So-called molecular machines, that is. The Third Rock Ventures-incubated startup will use the proceeds to bankroll continued work on the class of enzymes that “generate force and motion within cells,” Parikh told Endpoints News.

Torsten Mummenbrauer, ExeVir CEO

Scoop: Ex­e­Vir hits pause on lla­ma-de­rived Covid an­ti­body amid Omi­cron vari­ants, shifts fo­cus to sec­ond-gen work

ExeVir has returned to the drawing board after pausing work on its first-generation llama-derived Covid-19 antibody and is turning its R&D focus toward a preclinical second-gen attempt, Endpoints News has learned.

The Belgian biotech terminated a study of the antibody, dubbed XVR011, last month due to “change in company strategy for phase 2 design,” according to an update on The biotech still awaits some data to confirm the scope of Omicron and its subvariants’ effect on the antibody, but ExeVir is likely to move forward without its first shot at treating the pandemic disease, CEO Torsten Mummenbrauer told Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Damien McDevitt, Aspen Neuroscience CEO

Ex­clu­sive: As­pen Neu­ro­science col­lects large Se­ries B to com­pete against Bay­er's Parkin­son's cell ther­a­py

Damien McDevitt thinks frequently about the name Aspen Neuroscience. Specifically, should the neuroscience portion be dropped as the San Diego biotech considers expanding beyond the CNS?

McDevitt, the 21-year GlaxoSmithKline veteran and former Akcea Therapeutics CEO who took over the helm of Aspen in January 2021, now has even more deep-pocketed investors to help him and his 60-plus employee team consider their voyage beyond Parkinson’s thanks to a $147.5 million Series B.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Tom Lemberg, Curebase CEO

DCT start­up look­ing to forge bet­ter com­mu­ni­ty re­la­tion­ships nets a mod­est Se­ries B

The decentralized clinical trial industry went through a huge boom during the Covid-19 pandemic as biotechs and Big Pharma companies alike were forced to shift gears. Looking to capitalize on that momentum, a San Francisco startup is raising funds to ensure closer partnerships with the communities DCTs serve.

Curebase pulled together a $40 million Series B on Thursday, roughly 13 months after closing its Series A. While on the surface this may seem like another DTC company, CEO Tom Lemberg tells Endpoints News the company is looking to separate itself from the pack by going straight to the community to bring greater diversity to clinical trials.

Dominik Schumacher, Tubulis co-founder and CEO

How do you pack 20 years of ADC learn­ings in­to one com­pa­ny? Tubu­lis has $63M more to an­swer that

More than two decades have passed since the first antibody-drug conjugate went on the market. But according to a biotech startup out of Germany, the space is really just beginning to flourish.

And if Tubulis gets its way, it will play a big part in designing the ADCs that will be deployed in cancer treatments of tomorrow.

Andera Partners led a new $63 million (€60 million) into the company, which brought new investors Evotec and Fund+ into the syndicate, joining Bayern Kapital, BioMedPartners, coparion, High-Tech Gründerfonds, OCCIDENT and Seventure Partners.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Catalio co-founders George Petrocheilos and Jacob Vogelstein

Af­ter 45 in­vest­ments in two years, Catalio reels in more funds to back 30 ad­di­tion­al com­pa­nies

Catalio Capital Management has seen a flurry of deal activity across its 45 portfolio companies in its nascent history, and the investor is ready to bankroll the next slate of drug developers, device makers, diagnostics creators and data companies with its third fund.

The New York, Baltimore and London investment shop picked up $381 million, nearly 4 times the size of its $100 million second fund and leaps and bounds bigger than its $15 million first fund when it launched in 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Marino Garcia, Dianthus CEO

5AM, Avid­i­ty, Fi­deli­ty lead $100M in­fu­sion in­to next-gen, tar­get­ed com­ple­ment ap­proach

When the FDA first approved Alexion’s Soliris — then eculizumab — in 2007, experts celebrated how the first-of-its-kind drug transformed the way physicians could treat a rare disease called paroxysmal nocturnal hemoglobinuria.

As Soliris racked up more landmark OKs, the C5 inhibitor also became a wildly successful franchise for the company, spurring blockbuster sales that led to a follow-on drug and a $39 billion buyout by AstraZeneca while inspiring new players to jump into the complement space.

James Boylan, Enavate Sciences CEO

James Boy­lan snags $300M to hunt for biotech deals af­ter leav­ing SVB

After three decades in healthcare investment banking, culminating in serving as SVB president, James Boylan is headed to the other side of the industry.

Specifically, he’s the new CEO of Patient Square Capital’s biotech investment company Enavate Sciences, which launches Monday with $300 million to go after “middle innings” private and public biotechs.

“The opportunity to really sit shoulder to shoulder with people that used to be my clients and now will be my partners was so exciting it pulled me out of retirement,” Boylan told Endpoints News after taking a year off to be with family.